Literature DB >> 24771164

Frequency of symptoms and signs of primary vascular dysregulation in Swiss and Korean populations.

K Konieczka1, H J Choi2, S Koch1, A Schoetzau1, D Küenzi1, D M Kim3.   

Abstract

BACKGROUND: Primary vascular dysregulation syndrome (also called Flammer syndrome) is related to certain eye diseases, particularly normal tension glaucoma. Primary vascular dysregulation is characterized by a number of symptoms and signs (e.g., cold hands and/or feet, low blood pressure), that occur more frequently in subjects with primary vascular dysregulation compared to the general population. The aim of the present study was to test and compare the relative frequency of symptoms and signs related to primary vascular dysregulation in unselected populations in Switzerland and Korea. SUBJECTS AND METHODS: Swiss (n=259) and Korean (n=1116) subjects filled out our questionnaire containing 15 questions related to symptoms and signs of primary vascular dysregulation.
RESULTS: In the populations studied, seven of 15 symptoms and signs of primary vascular dysregulation (increased smell perception, increased pain sensation, increased response to certain drugs, low body mass index, feeling cold, cold hands and/or feet, and headaches) occurred significantly more often in the Swiss population than in the Korean population, whereas five symptoms and signs (reversible skin blotches, tendency toward perfectionism, long sleep onset time, tinnitus, and dizziness) occurred significantly more often in the Korean population.
CONCLUSION: The relative frequency of these symptoms and signs of primary vascular dysregulation in an unselected average population differs between Switzerland and Korea. Therefore, if a diagnosis of primary vascular dysregulation is based on the self-reported symptoms and signs of the patient, they must be compared with the frequency of symptoms and signs in the corresponding local population. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2014        PMID: 24771164     DOI: 10.1055/s-0034-1368239

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  7 in total

1.  Postmenopausal breast cancer: European challenge and innovative concepts.

Authors:  Ivica Smokovski; Milan Risteski; Jiri Polivka; Pavol Zubor; Katarzyna Konieczka; Vincenzo Costigliola; Olga Golubnitschaja
Journal:  EPMA J       Date:  2017-05-30       Impact factor: 6.543

2.  Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach?

Authors:  Pavol Zubor; Alexandra Gondova; Jiri Polivka; Petra Kasajova; Katarzyna Konieczka; Jan Danko; Olga Golubnitschaja
Journal:  EPMA J       Date:  2017-04-10       Impact factor: 6.543

3.  "Dry mouth" and "Flammer" syndromes-neglected risks in adolescents and new concepts by predictive, preventive and personalised approach.

Authors:  Analtoly Kunin; Jiri Polivka; Natalia Moiseeva; Olga Golubnitschaja
Journal:  EPMA J       Date:  2018-08-02       Impact factor: 6.543

4.  Multiple sclerosis and primary vascular dysregulation (Flammer syndrome).

Authors:  Katarzyna Konieczka; Simone Koch; Tatjana Binggeli; Andreas Schoetzau; Juerg Kesselring
Journal:  EPMA J       Date:  2016-06-15       Impact factor: 6.543

5.  "Pre-metastatic niches" in breast cancer: are they created by or prior to the tumour onset? "Flammer Syndrome" relevance to address the question.

Authors:  Rostyslav Bubnov; Jiri Polivka; Pavol Zubor; Katarzyna Konieczka; Olga Golubnitschaja
Journal:  EPMA J       Date:  2017-05-02       Impact factor: 6.543

Review 6.  Flammer syndrome.

Authors:  Katarzyna Konieczka; Robert Ritch; Carlo Enrico Traverso; Dong Myung Kim; Michael Scott Kook; Augusto Gallino; Olga Golubnitschaja; Carl Erb; Herbert A Reitsamer; Teruyo Kida; Natalia Kurysheva; Ke Yao
Journal:  EPMA J       Date:  2014-07-08       Impact factor: 6.543

7.  Relationship between normal tension glaucoma and Flammer syndrome.

Authors:  Katarzyna Konieczka; Hyuk Jin Choi; Simone Koch; Franz Fankhauser; Andreas Schoetzau; Dong Myung Kim
Journal:  EPMA J       Date:  2017-06-02       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.